Proactive Investors

COMPASS Pathways' psychedelic therapy for treatment-resistant depression is nearing FDA approval, with phase III trials showing rapid and durable efficacy. The company targets a 2027 launch, citing strong payer interest, robust infrastructure, and a large unmet patient need. A PTSD program is also advancing, according to a Morgan Stanley conference transcript.

COMPASS Pathways (CMPS) presented at Morgan Stanley's conference, targeting a 2027 launch for its psilocybin-based drug COMP360. The company reported strong clinical data, FDA progress, and a ready treatment network. Shares are up 171% year-to-date, trading near a 52-week high at $14.13, with a $1.96B market cap.

FDA held meetings on psychedelic drug development and PDUFA reauthorization. Definium reported successful Phase 3 trial data for its LSD drug, aiming for FDA approval. Biopharma companies presented positive lung cancer survival data. Novartis' asset stumbles caused a 13% share price drop.

COMPASS Pathways (CMPS) reported 52-week Phase 3 trial data for COMP360 in treatment-resistant depression, showing sustained efficacy and safety. The results suggest long-term symptom relief, impacting future treatment models. Analysts project significant revenue and earnings growth by 2029, with varying upside estimates. The next key catalyst is the Phase 3 COMP006 readout and regulatory progress.

Compass Pathways (CMPS) reported that its psilocybin treatment COMP360 showed sustained benefits for treatment-resistant depression in a Phase 3 trial. Shares rose 5% in pre-market trading, extending recent gains. The FDA granted a rolling NDA review, with a commercial launch targeted for 2027.

Compass Pathways (CMPS) shares rose 4% after 52-week data from its Phase III study showed sustained depression relief with infrequent dosing. Analysts at Jefferies expect FDA approval, estimating a $1.5B peak sales opportunity. The company aims to complete its New Drug Application submission by Q4 2026, with a planned launch in early 2027.